menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Regulatory Environment' ×
Ray Huml
With patent expirations looming, biologic companies must innovate – or litigate – to protect their market share.
Read More
Ray Huml
Randy Thomas
Exploring the IT infrastructure healthcare organizations will need to support their move to Advanced APMs.
Read More
Liz Allen
Why the EMA is updating its Phase I one safety guidance for volunteers, and how sponsors should respond.
Read More
Caroline Freeman
Daniel Vazquez
Latin America is a center for biopharmaceutical growth, but shifting regulations mean companies need keen insights and boots on the ground to navigate this complex marketplace.
Read More
RobinHuff
The European Medicines Agency clarifies key concepts on orphan drug designation and marketing authorization — which may provide greater predictability for drug developers.
Read More
Annette Williams
How automation, harmonization and outsourcing are changing the way the industry conducts pharmacovigilance.
Read More
Chris Bamford
How Regulation 536/2014 will impact the way developers conduct research in the EU.
Read More
Barbara Gillespie
A follow-up report on the CardioVascular Clinical Trialists Forum, and the opportunities to enhance collaboration between cardiologists, endocrinologists, and nephrologists for the benefit of patients with chronic kidney disease.
Read More